COMMUNIQUÉS West-GlobeNewswire

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
14/06/2024
Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024 RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on [...]
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
14/06/2024
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity A third cohort is ongoing following FDA’s OPTIMUS guidance MADRID and [...]
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
14/06/2024
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American [...]
BetterLife Announces Closing of a Private Placement
14/06/2024
VANCOUVER, British Columbia, June 14, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and [...]
Sharecare wins 22 Digital Health Awards in Spring 2024 competition
14/06/2024
Company recognized for its flagship well-being and health navigation platform, as well as clinically validated programs, digital therapeutics, and patient education content ATLANTA, June 14, 2024 (GLOBE NEWSWIRE) -- [...]
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
14/06/2024
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an [...]
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
14/06/2024
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational [...]
Intellia Therapeutics Names Brian Goff to its Board of Directors
14/06/2024
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress
14/06/2024
-- Researchers Shared Findings Including a Clinically Manageable Safety Profile and Anti-leukemic Activity with WU-CART-007 in Patients with R/R T-ALL/LBL and Previously Treated with Existing Therapies -- U.S. Biotech [...]
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
14/06/2024
Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic protoporphyria (EPP) and support development path forward Additional [...]
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
14/06/2024
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains and objective reduction [...]
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
14/06/2024
Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and [...]
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
14/06/2024
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage LONDON and NEW YORK, June 14, 2024 (GLOBE [...]
TScan Therapeutics Announces Updates to its Board of Directors
14/06/2024
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role of Chair WALTHAM, Mass [...]
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
14/06/2024
Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients HOUSTON, June 14, [...]
Tilray Beverages Announces Campaign to Raise Awareness for Men’s Health
14/06/2024
NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or “Tilray”) (Nasdaq | TSX: TLRY), a leading global lifestyle and consumer packaged goods company inspiring and empowering the worldwide [...]
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
14/06/2024
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory [...]
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
14/06/2024
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff [...]
Greenwich LifeSciences Announces $2.5 Million Private Placement
14/06/2024
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO [...]

Pages